

PTAB Not a Problem for Ravgen Verdict

By Scott Graham

Last September, when **Ravgen** won a \$272 million jury verdict in a case over prenatal diagnostics, I cautioned that the Patent Trial and Appeal Board was reviewing Ravgen's patents.

You can throw that caution to the wind now. Ravgen's patents have survived a series of IPR decisions, including claim 132 of the 7,332,277 patent, which undergirds the \$272 million verdict against **Laboratory Corp. of America**.

Ravgen settled similar litigation with **Quest Diagnostics** in October. It's still

doing battle in district courts and the PTAB with **Illumina, Ariosa Diagnostics, Myriad Genetics, Biora Therapeutics** and **Natera**.

Ravgen was back before **Judge Alan Albright** in the Western District of Texas on Wednesday to argue post-trial motions with Lab Corp. "We are hoping that the Court enhances the verdict for willfulness," Ravgen's lead trial lawyer, **Desmarais partner John Desmarais**, said in a written statement.

Ravgen's team on the IPRs included Desmarais partners



Gaby Higgins of Desmarais

Courtesy Photo

Gaby Higgins and **Sam Ha**, of counsel **Theodoros Konstantakopoulos** and **Michael Stramiello**, and associates **Brian Matty** and **Joze Welsh**.